Emerging Approaches to Cancer Immunotherapy
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 2592
Special Issue Editors
Interests: microbiota; PRRs; gut–brain axis; innate immunity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent years, immunotherapy has established as a first line treatment against several types of cancer. The emergence of this field, compared to chemotherapy, is enabling new promising tools to treat patients. Strategies such as checkpoint inhibitors and chimeric-antigen receptor (CAR) technology are leading new possibilites and better outcomes for patients. Nevertheless, as cancer researchers and physicians already know, not all tumors respond equally to immunotherapy, and there is still room for improvement.
For this Special Issue, we would like to bring together recent advances and novel approaches that enable effective and safe cancer immunotherapy, with the goal to further facilitate its clinical translation. It is intended to cover a broad spectrum of related topics, including adoptive cell therapy, checkpoint inhibitors, monoclonal antibodies, cancer vaccines and immunomodulatory agents, among others. This Special Issue will present original research work as well as scientific reviews, aiming to address the cutting edge advances in cancer immunotherapy.
Dr. Eva Latorre
Dr. Joaquin Marco-Brualla
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- monoclonal antibodies
- adoptive cell therapy
- cancer vaccines
- immunoediting
- checkpoint inhibitors
- immuno-genic cell death
- immunomodulatory agents